Monoclonal antibody basiliximab with low cyclosporine dose as initial immunosuppression.
Boletis
J N
JN
Department of Nephrology, Laiko General Hospital, Athens, Greece.
Theodoropoulou
H
H
Hiras
T
T
Stamatiadis
D
D
Darema
M
M
Psimenou
E
E
Stathakis
C
C
Kostakis
A
A
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000097:blood / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000517:prevention & control; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D011183:Postoperative Complications / Q000517:prevention & control; D011993:Recombinant Fusion Proteins
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D016572:Cyclosporine; D000077552:Basiliximab; D003404:Creatinine; D008775:Methylprednisolone